Patents by Inventor Nina Liu
Nina Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965020Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.Type: GrantFiled: May 17, 2023Date of Patent: April 23, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chia-Yang Lin, Samuel Davis
-
Patent number: 11905322Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD- L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.Type: GrantFiled: May 3, 2021Date of Patent: February 20, 2024Assignee: Albert Einstein College of MedicineInventors: Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
-
Publication number: 20240019443Abstract: Methods for characterizing protein complexes formed between protein drug products and soluble ligands are provided herein. The disclosed methods can determine the size, heterogeneity, and conformation of protein complexes.Type: ApplicationFiled: July 6, 2023Publication date: January 18, 2024Inventors: Nina Liu, Michael Rosconi, Erica Pyles
-
Publication number: 20230340105Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.Type: ApplicationFiled: May 17, 2023Publication date: October 26, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chia-Yang Lin, Samuel Davis
-
Patent number: 11754569Abstract: Methods for characterizing protein complexes formed between protein drug products and soluble ligands are provided herein. The disclosed methods can determine the size, heterogeneity, and conformation of protein complexes.Type: GrantFiled: August 28, 2019Date of Patent: September 12, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Nina Liu, Michael Rosconi, Erica Pyles
-
Patent number: 11708407Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.Type: GrantFiled: February 7, 2022Date of Patent: July 25, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chia-Yang Lin, Samuel Davis
-
Publication number: 20220235126Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.Type: ApplicationFiled: February 7, 2022Publication date: July 28, 2022Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chiayang Lin, Samuel Davis
-
Publication number: 20220195030Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.Type: ApplicationFiled: February 7, 2022Publication date: June 23, 2022Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chiayang Lin, Samuel Davis
-
Patent number: 11352413Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.Type: GrantFiled: May 9, 2017Date of Patent: June 7, 2022Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINEInventors: Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
-
Publication number: 20220098274Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.Type: ApplicationFiled: May 3, 2021Publication date: March 31, 2022Inventors: Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
-
Publication number: 20210040197Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.Type: ApplicationFiled: August 7, 2020Publication date: February 11, 2021Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chiayang Lin, Samuel Davis
-
Publication number: 20200072844Abstract: Methods for characterizing protein complexes formed between protein drug products and soluble ligands are provided herein. The disclosed methods can determine the size, heterogeneity, and conformation of protein complexes.Type: ApplicationFiled: August 28, 2019Publication date: March 5, 2020Inventors: Nina Liu, Michael Rosconi, Erica Pyles
-
Publication number: 20190127439Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.Type: ApplicationFiled: May 9, 2017Publication date: May 2, 2019Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.Inventors: Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
